


1/13



2/13




FIG. 2A

3/13




FIG.2B

4/13




FIG. 3A




FIG. 3B

5/13




FIG. 4A




FIG. 4B

6/13

Non-treated




FIG. 5A

Doxorubicin-treated tumors




FIG. 5C




FIG. 5B

7/13




FIG. 6

8/13

	Control	Doxo (2x20 mg/ kg)
Tumor/ Kidney	0.86	0.59
Tumor/ Heart	1.07	5.69
Tumor/ Liver	0.88	4.68
Tumor/ Muscle	1.61	8.66
Tumor/ Fast tissue	6.60	5.20
Tumor/ Spleen	2.42	3.86
Tumor/ Lung	1.07	2.52
Tumor/ Blood	1.43	3.50
Tumor/Small intestine	1.18	2.26
Tumor	0.07	1.28

FIG. 7

9/13




FIG. 8B




FIG. 8A

10/13




FIG. 9B






FIG. 9A

11/13



Contralateral side kidney

FIG. 10B



Ischemic kidney

FIG. 10A

12/13




FIG. 11

13/13




FIG. 12